1.Kidney disease in antiretroviral-naïve HIV-positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. AC Achhra, A Mocroft, MJ Ross, L Ryom, GM Lucas, H Furrer, J Neuhaus, C Somboonwit, M Kelly, JM Gatell, CM Wyatt for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):55-63. Abstract
2 Assessment of arterial elasticity among HIV-positive participants with high CD4 cell counts: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. JV Baker, NW Engen,K Huppler Hullsiek, C Stephan, MK Jain, P Munderi, S Pett, D Duprez for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):109-118. Abstract
3 Global HIV-1 transmitted drug resistance in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. JD Baxter, D Dunn, E White, S Sharma , Am Geretti, MJ Kozal, MA Johnson, S Jacoby, JM Llibre, J Lundgren for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):77-87.Abstract
4 Factors associated with plasma IL-6 levels during HIV infection. ÁH Borges, JL O'Connor, AN Phillips, FF Rönsholt, S Pett, MJ Vjecha, MA French, JD Lundgren or the INSIGHT SMART and ESPRIT Study Groups and the SILCAAT Scientific Committee. Factors associated with plasma IL-6 levels during HIV infection. J Infect Dis 2015; 212:585-595.Abstract
5 Prevalence and risk factors for low bone mineral density in untreated HIV infection: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. A Carr, B Grund, J Neuhaus, A Schwartz, JI Bernardino, D White, S Badel-Faesen, A Avihingsanon, K Ensrud, J Hoy for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):137-146. Abstract
6 Investigation of efavirenz discontinuation in multi-ethnic populations of HIV-positive individuals by genetic analysis. Cummins NW, Neuhaus J, Chu H, Neaton J, Wyen C, Rockstroh JK, Skiest DJ, Boyd MA, Khoo S, Rotger M, Telenti A, Weinshilboum R, and Badley AD for the INSIGHT Study Group.
E Bio Medicine 2015; 2(7):706-712. doi: 10.1016/j.ebiom.2015.05.012. eCollection 2015. Abstract
7 Reported consent processes and demographics: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Denning E, Sharma S, Smolskis M, Touloumi G, Walker S, Babiker A, Clewett M, Emanuel E, Florence E, Papadopoulos A, Sánchez A, Tavel J, Grady C for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):24-29 .Abstract
8 Plasma levels of cytokines and chemokines and the risk of mortality in HIV-infected individuals: a case-control analysis nested in a large clinical trial. French MA, Cozzi-Lepri A, Arduino RC, Johnson M, Achhra AC, Landay A for the INSIGHT SMART Study Group.
AIDS 2015; 29:847–851. Abstract
9 Community perspective on the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Geffen N, Aagaard P, Corbelli GM, Meulbroek M, Peavy D, Rappoport C, Schwarze S, Collins S for the INSIGHT Community Advisory Board.
HIV Med 2015; 16:(suppl S1):10-13. Abstract
10 Challenges, successes and patterns of enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Grarup J, Rappoport C, Engen NW, Carey C, Hudson F, Denning E, Sharma S, Florence E, Vjecha MJ for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):14-23. Abstract
11 Investigating the efficacy of clinical trial monitoring strategies: design and implementation of the cluster randomized START Monitoring Substudy. Huppler Hullsiek K, Kagan JM, Wyman N, Grarup J, Hudson F, Denning ET, Carey C, Courtney-Rodgers D, Finley EB, Jansson PO, Pearson MT, Peavy DE, Belloso WH for the INSIGHT START Monitoring Substudy Group.
Ther Innov Regul Sci 2015; 49:225-233. Abstract
12 INSIGHT FLU005: an anti-influenza hyperimmune iIntravenous immunoglobulin pilot study. INSIGHT FLU005 IVIG Pilot Study Group.
J Infect Dis 2015; pii: jiv453. Epub ahead of print. Abstract
13 Why START? Reflections that led to the conduct of this large long-term strategic HIV trial. INSIGHT START Study Group. HIV Med 2015; 16:(suppl S1):1-9. Abstract
14 Initiation of antiretroviral therapy in early asymptomatic HIV Infection. INSIGHT START Study Group.
N Engl J Med 2015; 373:795-807. Abstract
See also: Antiretroviral Therapy in Early HIV Infection (letters to editor and response by Lundgren J, Babiker AG, Neaton JD). (editorial) Lopez-Cortes LF, Gutierrez-Valencia A, Ben-Marzouk-Hidalgo OJ; Corrao S, Prestileo T, Di Lorenzo F.
N Engl J Med 2015; 374:393-394..
15 Pulmonary function in an international sample of HIV-positive, treatment-naïve adults with CD4 counts >500 cells/μL: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Kunisaki KM, Niewoehner DE, Collins G, Nixon DE, Tedaldi E, Akolo C, Kityo C, Klinker H, La Rosa A, Connett JE for the INSIGHT Start Study Group.
HIV Med 2015; 16:(suppl S1):119-128. Abstract
16 Clinical and demographic factors associated with low viral load in early untreated HIV infection in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Law MG, Achhra A, Deeks SG, Gazzard B, Migueles SA, Novak RM, Ristola M for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):37-45. Abstract
17 Quality of life assessment among HIV-positive persons entering the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Lifson AR, Grandits GA, Gardner EM, Wolff MJ, Pulik P, Williams I, Burman WJ for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):88-96. Abstract
18 Baseline prevalence and predictors of liver fibrosis among HIV-positive individuals: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Matthews GV, Neuhaus J, Bhagani S, Mehta SH, Vlahakis E, Doroana M, Naggie S, Arenas-Pinto A, Peters L, Rockstroh JK for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):129-136.Abstract
19 Development and validation of a risk score for chronic kidney disease in HIV infection using prospective cohort data from the D:A:D study. Mocroft A, Lundgren JD, Ross M, Law M, Reiss P, Kirk O, Smith C, Wentworth D, Neuhaus J, Fux CA, Moranne O, Morlat P, Johnson MA, Ryom L on behalf of the Data on Adverse Events (D:A:D) study group, the Royal Free Hospital Clinic Cohort and the INSIGHT SMART and ESPRIT study groups.
PLoS Med 2015; 12(3):e1001809. doi: 10.1371. Abstract
20 A simple self-reported adherence tool as a predictor of viral rebound in people with viral suppression on antiretroviral therapy. O'Connor JL, Gardner EM, Esser S, Mannheimer SB, Lifson AR, Telzak EE, Phillips AN for the iNSIGHT SMART Study Group.
HIV Med 2015; DOI: 10.1111/hiv.12284. Abstract
21 Transmission risk behaviour at enrolment in participants in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Rodger AJ, Lampe FC, Grulich AE, Fisher M, Friedland G, Phanuphak N, Bogner JR, Pereira LC, Rietmeijer C, Burman W, Phillips AN for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):64-76. Abstract
21 Demographic and HIV-specific characteristics of participants enrolled in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Sharma S, Babiker AG, Emery S, Gordin FM, Lundgren JD, Neaton JN, Bakowska E, Schechter M, Wiselka MJ, Wolff MJ for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):30-36. Abstract
22 Baseline cardiovascular risk in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Soliman EZ, Sharma S, Arastéh K, Wohl D, Achhra A, Tambussi G, O'Connor J, Stein JH, Duprez DA, Neaton JD, Phillips A for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):46-54. Abstract
23 Factors associated with neurocognitive test performance at baseline: a substudy of the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial. Wright EJ, Grund B, Cysique LA, Robertson KR, Brew BJ, Collins G, Shlay JC, Winston A, Read TRH, Price RW for the INSIGHT START Study Group.
HIV Med 2015; 16:(suppl S1):97-108. Abstract